Core Viewpoint - Medicus Pharma Ltd. is actively engaging in clinical development for innovative treatments in oncology and urology, with significant upcoming events and ongoing studies that may impact its market position and growth potential [1][6]. Group 1: Company Events - Medicus Pharma Ltd. will participate in the BTIG Virtual Biotech Conference 2025, with Dr. Raza Bokhari, Executive Chairman and CEO, scheduled for a Fireside Chat on July 30, 2025, at 9:20 a.m. ET [1][2]. - The Fireside Chat will be livestreamed for registered investors, and a recording will be available post-event [2]. Group 2: Clinical Development - The company's lead asset, SkinJect Inc., is focused on a novel treatment for non-melanoma skin cancer, particularly basal cell carcinoma (BCC), utilizing a patented dissolvable doxorubicin-containing microneedle array (D-MNA) [3][9]. - A Phase 2 clinical study (SKNJCT-003) is currently underway across nine clinical sites in the U.S., with an interim analysis showing over 60% clinical clearance after randomizing more than 50% of the targeted 60 patients [4]. - The investigational review board has increased the participant count for SKNJCT-003 to 90 subjects, and the company is also expanding clinical trial sites into Europe [4]. - A separate clinical study (SKNJCT-004) is being conducted in the UAE, randomizing 36 patients across four sites, with Cleveland Clinic Abu Dhabi as the principal investigator [5]. Group 3: Strategic Acquisitions - In June 2025, Medicus Pharma Ltd. announced a definitive agreement to acquire Antev Ltd., a UK-based clinical stage biotech company developing Teverelix for advanced prostate cancer patients [6][10]. - The acquisition is expected to close before the end of August 2025, subject to certain conditions including shareholder approval [6][10].